Synagis and Busulfan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Synagis (palivizumab) and Busulfan (busulfan). Common drug interactions include cardiac hypertrophy among females and aplastic anaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Synagis and Busulfan. It is created by eHealthMe based on reports of 35 people who take the same drugs from the FDA, and is updated regularly.

What is Synagis?

Synagis has active ingredients of palivizumab. eHealthMe is studying from 19,114 Synagis users. Check the latest studies of Synagis.

What is Busulfan?

Busulfan has active ingredients of busulfan. eHealthMe is studying from 14,527 Busulfan users. Check the latest studies of Busulfan.

On Jul, 15, 2026

35 people who take Synagis and Busulfan together, and have interactions are studied.

What are the common drug interactions of Synagis and Busulfan, by gender? *:

female:

Cardiac hypertrophy (thickening of the heart muscle)

male:

Aplastic anaemia (blood disorder in which the body's bone marrow doesn't make enough new blood cells)
Febrile neutropenia (fever with reduced white blood cells)
Pulmonary haemorrhage (acute bleeding from the lung)
Venoocclusive liver disease (small veins in the liver are obstructed)
Bone marrow failure
Stomatitis (inflammation of mucous membrane of mouth)
Abdominal pain
Clostridial infection (infectious conditions by clostridium bacteria)
Conjunctivitis (pink eye)
Diarrhoea

What are the common drug interactions of Synagis and Busulfan, by age (0-1 to 60+)? *:

0-1:

Aplastic anaemia (blood disorder in which the body's bone marrow doesn't make enough new blood cells)
Febrile neutropenia (fever with reduced white blood cells)
Pain
Feeding disorder (when children refuse to eat certain food groups)
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Mucosal inflammation (infection of mucous membrane)
Portal vein thrombosis (venous thrombosis affecting the hepatic portal vein)
Pulmonary haemorrhage (acute bleeding from the lung)
Venoocclusive liver disease (small veins in the liver are obstructed)
Stomatitis (inflammation of mucous membrane of mouth)

2-9:

Pulmonary hypertension (increase in blood pressure in the lung artery)
Restrictive cardiomyopathy (a condition in which the walls of the lower chambers of the heart (the ventricles) are abnormally rigid and lack the flexibility)
Engraft failure
Gastrointestinal candidiasis (fungal infection of gastrointestinal tract)
Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)
Hyperglycaemia (high blood sugar)
Hypernatraemia (an abnormally high plasma concentration of sodium ions)
Hypoalbuminaemia (levels of albumin in blood serum are abnormally low)
Jaundice (a yellowish pigmentation of the skin, the conjunctival membranes)
Neutropenia (an abnormally low number of neutrophils)

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 10 people, 28.57%
Neuroblastoma (a cancer that forms in your nerve tissue): 3 people, 8.57%

* Approximation only. Some reports may have incomplete information.

Do you take Synagis and Busulfan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously